Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs REGENXBIO Inc. (RGNX)

DiaMedica Therapeutics, Inc. and REGENXBIO Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and REGENXBIO Inc. are of similar size ($487.5M and $487.2M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −113.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, DiaMedica Therapeutics, Inc. leads on 6 and REGENXBIO Inc. on 6.

Valuation

Metric DMAC RGNX Biotechnology median
P/E n/m n/m 10.60
P/S n/m 3.21 9.40
P/B 13.30 3.33 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1.61 9.02
Earnings yield (7.61%) (42.52%) (32.88%)
Free cash flow yield (6.19%) (31.38%) (23.13%)

Profitability

Metric DMAC RGNX Biotechnology median
Gross margin 0.00% 87.54% 68.51%
Operating margin 0.00% (95.68%) 0.00%
Net margin 0.00% (113.85%) 0.00%
Free cash flow margin 0.00% (100.58%) 0.00%
Return on equity (114.62%) (113.24%) (51.96%)
Return on assets (98.18%) (35.36%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC RGNX Biotechnology median
Revenue growth (TTM) — (4.59%) 6.76%
EPS growth (last fiscal year) (16.67%) 18.08% 29.88%
Revenue growth, 5-year CAGR — 1.97% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC RGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 4.74 4.97
Net debt to EBITDA 1.70 1.58 1.01

Dividend

Metric DMAC RGNX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DMAC RGNX Biotechnology median
Market cap 487.49m 487.18m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack